SME Times is powered by   
Search News
Just in:   • SpiceJet re-introduces 'Zero Change fee' offer  • 'Good' progress made at nuclear talks but issues remain: Iran  • Fiscal package may be on cards to maintain economic recovery amid Covid 2.0  • Striking taxi drivers demands unreasonable: Goa tourism body  • Govt notifies Rs 6k cr PLI scheme for AC, LED light manufacturing 
Last updated: 26 May, 2017  

Cipla.9.Thmb.jpg Cipla's Q4 consolidated net loss at Rs 62 cr

   Top Stories
» Fiscal package may be on cards to maintain economic recovery amid Covid 2.0
» FICCI writes to 25 CMs on Covid management
» Regulation of insolvent firms' shares still remains a dilemma
» ECLGS 2.0 now covers SMA-1 borrowers
» Forex reserves up by over $4 bn
SME Times News Bureau
Global pharmaceutical firm Cipla on Thursday reported a consolidated net loss of Rs 62 crore for the fourth quarter (Q4) of 2016-17.

According to the company, its consolidated net loss during the quarter under review declined to Rs 62 crore from Rs 93 crore in the corresponding period of 2015-16.

However, Cipla's total income for the fourth quarter increased by 8.1 percent to Rs 3,582 crore from Rs 3,315 crore earned during Q4 of FY16.

"While the quarterly results are off the mark due to a tough operating environment and certain one-offs, we delivered on our goal of improving base EBITDA percentage year-on-year by more than 200 bps," said Umang Vohra, MD and Global CEO, Cipla.

On a full financial year 2016-17 basis, the company reported that its consolidated net profit decreased by 26 percent to Rs 1,006 crore from Rs 1,360 crore in 2015-16.

On the other hand, Cipla's consolidated total income from operations during the fiscal under review edged higher by 6.1 percent to Rs 14,630 crore from Rs 13,790 crore.

"We have achieved significant progress on our identified key priorities and have strengthened our core business through consolidation, complexity reduction and deepening our presence in priority markets," Vohra said.

"This year, we have had good traction on our pipeline with 32 US ANDA filings
and a proof of concept of our capabilities for the respiratory franchise for the advanced markets with approval of Sereflo in UK and Albuterol MDI filing in the US."

The company's Board of Directors has recommended a dividend of Rs. 2 per equity share (face value Rs. 2 per equity share) for the year 2016-17, subject to the shareholders' approval.
Print the Page Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 18 Apr, 2021
  Daily Poll
COVID-19 has directly affected your business
 Can't say
  Commented Stories
» Covid second wave: Lockdown or no lockdown(2)
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter